Planven Entrepreneur Ventures
VC Fund
Zürich, Switzerland
Planven Entrepreneur Ventures is a VC fund in Zürich focused on Software and Cyber Security. Venutre Capital Fund that invests European entrepreneurs’ money in advanced technology solutions for fast growing B2B markets leveraging on a unique due diligence strategy and a proven proprietary deal sourcing
- Total investments:
- 26
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Planven Entrepreneur Ventures invests in
SoftwareCyber SecurityInformation TechnologyIaaSComputer
Stages Planven Entrepreneur Ventures invests in
Series ASeries BSeries CVenture - Series UnknownSeed
Countries Planven Entrepreneur Ventures invests in
IsraelUnited States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dror Ginzberg
|
|||
Giovanni Canetta Roeder
|
|||
Ohad Finkelstein
|
|||
2 more contacts available
Investment Focus
Industry
- Software 7 (27%)
- Cyber Security 4 (15%)
- Information Technology 3 (12%)
- IaaS 2 (8%)
- Computer 2 (8%)
Stage
- Series A 6 (23%)
- Series B 6 (23%)
- Series C 5 (19%)
- Venture - Series Unknown 2 (8%)
- Seed 1 (4%)
Country
- Israel 8 (31%)
- United States 6 (23%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dror Ginzberg
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
Giovanni Canetta Roeder
Managing Partner & CEO
|
Managing Partner & CEO | Total investments: 0 | Find email | |
|
Ohad Finkelstein
Chairman
|
Chairman | Total investments: 17 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Encore AI
|
Insait transforms conversational data into revenue-generating AI agents by combining LLMs with proprietary recommendation engines. Unlike static knowledge bases, Insait learns from both successful and unsuccessful interactions to continuously improve agent performance. The platform enables AI agents to manage complex, high-value conversations—suchas loans, life insurance, and private lending—rather than just simple support queries. Its unique architecture allows learning from one agent to instantly flow to all others, creating a flywheel effect that improves conversion rates and unlocks strategic business insights from every customer interaction. | $30M / Series A / Jul 29, 2026 | |
Seraphic Security
|
The browser has become the main productivity tool for employees due to driving trends like working remotely, BYOD, and web-based SaaS applications. This has turned the browser into the largest surface of attack for businesses, both by employee policy infringement and attacks by hackers. Legacy solutions fail to protect the browser, compromiseuser experience, and are difficult to deploy and operate. This is where Seraphic's unique value benefits customers all over the world. Seraphic enables secure browsing for your employees and contractors working from their corporate or personal devices, so they can enjoy full productivity without risk.Seraphic is a unique browser security solution that protects enterprise assets and provides your security team with advanced governance and policy enforcement. It's based on innovative (patent pending) technology - providing robust protection against all browser attacks, including full protection against zero-day and unpatched n-day attacks. Seraphic is easy to deploy, has no impact on performance, leaves user experience untouched, and is fully compatible across all browsers and devices (Including PC, Mac, Linux & Mobile).With Seraphic, you are a few minutes away from closing the most significant blind spot in your organization's cyber defense. | $29M / Series A / Jan 30, 2025 | |
Ibex Medical Analytics
|
Ibex Medical Analytics was conceived when its two founders were looking for ways to apply their skills to contribute to human well-being. They were captivated with the opportunity presented by applying artificial intelligence (AI) to medicine and, in particular, the potential it holds for advancing cancer care. They decided to combine theiraccumulated knowledge of AI, data science, image analysis, and machine learning, and apply it to cancer diagnostics in digital pathology.Today, Ibex is a multidisciplinary team comprised of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: Applying AI to cancer diagnostics, striving to improve patient outcomes and quality of life. | $55M / Series C / Sep 06, 2023 | |
Via
|
Via is a re-engineering public transit company that develops and provides on-demand public mobility solutions for commuters. The company transforms public transit from a regulated system of rigid routes and schedules to a fully dynamic, on-demand network. Via's mobile app connects passengers who are headed the same way, allowing riders toseamlessly share a premium vehicle. The platform operates in the United States and in Europe through its joint venture with Mercedes-Benz Vans, ViaVan. Via's technology is deployed worldwide through partner projects with public transportation agencies, private transit operators, taxi fleets, private companies, and universities, integrating with public transit infrastructure to power cutting-edge on-demand mobility.Via's software offers an end-to-end solution for planning, optimizing, and operating efficient and equitable transit systems, thereby unlocking opportunity for all and constructing resilient cities for the future. | $110M / Venture - Series Unknown / Feb 13, 2023 | |
|
Ibex Medical Analytics
|
Ibex Medical Analytics was conceived when its two founders were looking for ways to apply their skills to contribute to human well-being. They were captivated with the opportunity presented by applying artificial intelligence (AI) to medicine and, in particular, the potential it holds for advancing cancer care. They decided to combine theiraccumulated knowledge of AI, data science, image analysis, and machine learning, and apply it to cancer diagnostics in digital pathology.Today, Ibex is a multidisciplinary team comprised of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: Applying AI to cancer diagnostics, striving to improve patient outcomes and quality of life. | $10M / Debt Financing / Nov 09, 2022 | |
Equalum
|
Equalum develops and markets a platform for real-time data ingestion and processing focused on Big Data for enterprises. It is the first Data Beaming platform, capable of instantly teleporting operational data from any source to real-time analytics environments. Built for scalability and ease of use, Equalum harnesses the power of Spark in anenterprise-grade environment – helping organizations accelerate past traditional ETL or open-source implementations. Nir Livneh founded it in June 2015, with its headquarters in Tel Aviv in Israel. | $14M / Series C / Aug 08, 2022 | |
Monogoto
|
Monogoto is a cloud-based cellular network. Its API-driven Infrastructure-as-a-Service was designed from the ground up with simplicity in mind to enable cellular connectivity with existing enterprise IT infrastructure. With hundreds of ready-to-use APIs, Monogoto offers cellular connectivity with edge to the cloud security for IoT, Private LTE, and5G use cases. Its services include full audit for all network events with anomaly detection and alerts automation. Monogoto’s enterprise-friendly solution enables customers to consume advanced cellular VAS with zero CAPEX and an “as-a-Service” business model. The Monogoto network is distributed globally with public connectivity in 180 countries. Helping companies to comply with regulation, the Monogoto solution supports on-premise local breakout topology for private LTE/5G networks. | $11M / Seed / Jun 09, 2021 | |
|
Ibex Medical Analytics
|
Ibex Medical Analytics was conceived when its two founders were looking for ways to apply their skills to contribute to human well-being. They were captivated with the opportunity presented by applying artificial intelligence (AI) to medicine and, in particular, the potential it holds for advancing cancer care. They decided to combine theiraccumulated knowledge of AI, data science, image analysis, and machine learning, and apply it to cancer diagnostics in digital pathology.Today, Ibex is a multidisciplinary team comprised of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: Applying AI to cancer diagnostics, striving to improve patient outcomes and quality of life. | $38M / Series B / Mar 09, 2021 | |
TechSee
|
TechSee is a technology and technical support company that specializes in visual technology and augmented reality. The company’s technology combines AI with deep machine learning, proprietary algorithms, and big data to deliver a scalable cognitive system that becomes smarter with every customer support interaction.It offers a smart visualinteractive platform that enables its users to interact with their customer through a live virtual channel and guide them using augmented reality and annotations. TechSee was founded by Eitan Cohen, Amir Yoffe, and Gabby Sarussi in 2015 and is headquartered in Tel Aviv, Israel. | $30M / Series C / Oct 26, 2020 | |
Hysolate
|
Hysolate enables organizations to isolate risky and sensitive activities on users’ endpoints with a local workspace that isolates applications and data. Hysolate has reinvented how an isolated virtual environment is instantly deployed on a user’s device and remotely managed from the cloud. With Hysolate you can “split” the user’s device into twoisolated environments so users can work freely and be productive without compromising security. Hysolate is backed by Bessemer Venture Partners, Innovation Endeavors, Team8 and Planven Capital. For more information, visit https://www.hysolate.com or follow Hysolate on Twitter @hysolatenow. | $10M / Venture - Series Unknown / Sep 17, 2020 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Software Investors
50,021 investors
Hardware Investors
40,144 investors
Consumer Investors
32,380 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
Software VC Funds
31,919 investors
Hardware VC Funds
30,945 investors
FAQ
What does Planven Entrepreneur Ventures invest in?
Planven Entrepreneur Ventures invests primarily in Software, Cyber Security and Information Technology startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Planven Entrepreneur Ventures?
Public channels for Planven Entrepreneur Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Planven Entrepreneur Ventures?
The team at Planven Entrepreneur Ventures includes Dror Ginzberg (General Partner), Giovanni Canetta Roeder (Managing Partner & CEO) and Ohad Finkelstein (Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
